The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is rec...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/88 |
| _version_ | 1797876158955520000 |
|---|---|
| author | K. E. Borisov |
| author_facet | K. E. Borisov |
| author_sort | K. E. Borisov |
| collection | DOAJ |
| description | The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime. |
| first_indexed | 2024-04-10T01:57:41Z |
| format | Article |
| id | doaj.art-8259c53c6f7349f48488cdcb67078313 |
| institution | Directory Open Access Journal |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| last_indexed | 2024-04-10T01:57:41Z |
| publishDate | 2014-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj.art-8259c53c6f7349f48488cdcb670783132023-03-13T08:44:32ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272014-07-010110211210.17650/1994-4098-2012-0-1-102-112103The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancerK. E. Borisov0Башкирский государственный медицинский университетThe review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime.https://ojrs.abvpress.ru/ojrs/article/view/88рак яичниковрецидивбесплатиновый интервалтопотеканеженедельное введение |
| spellingShingle | K. E. Borisov The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer Опухоли женской репродуктивной системы рак яичников рецидив бесплатиновый интервал топотекан еженедельное введение |
| title | The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_full | The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_fullStr | The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_full_unstemmed | The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_short | The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_sort | leadership of topotecan in the treatment of recurrent platinum resistant ovarian cancer |
| topic | рак яичников рецидив бесплатиновый интервал топотекан еженедельное введение |
| url | https://ojrs.abvpress.ru/ojrs/article/view/88 |
| work_keys_str_mv | AT keborisov theleadershipoftopotecaninthetreatmentofrecurrentplatinumresistantovariancancer AT keborisov leadershipoftopotecaninthetreatmentofrecurrentplatinumresistantovariancancer |